Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health · Grant
Overview
Supports laboratory and patient-based research into mechanisms linking incretin medicines, including GLP-1-related treatments, to cancer risk. Projects should investigate cancer-relevant effects beyond short-term weight loss or diabetes outcomes.
Eligibility
Wits may apply as a non-US higher education institution. Proposals must fit this call and the mission of a participating institute; institutional registrations and funder requirements apply.
Other deadlines
Next new-application deadline: 5 October 2026. Next renewal/resubmission/revision deadline, where permitted: 5 November 2026. Submit by 17:00 local time of the applicant organisation. Call expiration: 8 January 2027. This is separate from the application deadline.
Contact
National Institutes of Health · [email protected]
Keywords
Health sciences